MSCI Q2 Results Show Solid Execution but Valuation Caps Upside

What happened

MSCI's Q2 2026 earnings likely continued the strong momentum from Q1, with recurring subscription sales and retention remaining elevated near the 'best Q1 since 2022' levels. However, the underlying pressure from average basis-point fee erosion and the company's heavy reliance on buybacks to drive per-share growth persist. The stock, trading at ~33x forward P/E, already prices in sustained mid-teens growth, leaving little room for error. While the operating narrative is intact—high retention, growing private-assets traction—the valuation multiple offers no cushion. The market's muted reaction to a 'beat and maintain' guidance pattern suggests investors are waiting for clearer evidence of durable re-acceleration before paying up further.

Implication

The Q2 results reinforce MSCI's quality—high retention, double-digit organic growth, and aggressive buybacks—but the stock at $597+ already capitalizes this. With 33x P/E and leverage at 2.94x, any stumble in subscription sales or retention below 95% could trigger a 10-15% correction. Long-term investors should target entry near $560 (the assessed attractive zone) and wait for either a pullback or proof that private-assets growth accelerates sustainably above 12% run-rate.

Thesis delta

The Q2 print confirms the Q1 re-acceleration story is holding, not breaking—retention and net new sales likely remained healthy. However, the valuation argument has not shifted; the stock still trades above our $620 base-case implied value. The key change is that the 'proof period' is now three months shorter: we have one fewer quarter to call a trend. If Q3 delivers another quarter of net new recurring sales >$35M and retention >95%, the bull case gains credibility. For now, we stay WAIT because the risk of multiple compression outweighs the potential for upward guidance surprise.